Telaprevir Simmering, Flush Vertex Raises $320 Million More
Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.
Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.